Meta-analysis of Peginterferon Alpha Therapy for Chronic Hepatitis B
Author Information
Author(s): Li Wen-cong, Wang Mao-rong, Kong Ling-bo, Ren Wei-guang, Zhang Yu-guo, Nan Yue-min
Primary Institution: Third Hospital of Hebei Medical University
Hypothesis
Is pegylated interferon alpha-based therapy more effective than conventional therapies for HBsAg clearance or seroconversion in chronic hepatitis B patients?
Conclusion
PEG-IFNα-based therapy is more effective than LAM monotherapy for HBsAg clearance or seroconversion in chronic hepatitis B patients.
Supporting Evidence
- PEG-IFNα was superior to LAM in achieving HBsAg clearance.
- No significant difference was found between PEG-IFNα monotherapy and combination therapy with LAM.
- The absolute change in HBsAg clearance and seroconversion rates was low, about 3-6%.
Takeaway
This study found that a specific treatment for hepatitis B helps patients get rid of a virus marker better than another common treatment.
Methodology
Meta-analysis of controlled clinical trials published from 2004 to 2010.
Potential Biases
Potential publication bias was noted in some comparisons.
Limitations
The analysis included both high-quality and low-quality studies, which may weaken the conclusions.
Participant Demographics
Patients with chronic hepatitis B, both HBeAg-positive and HBeAg-negative.
Statistical Information
P-Value
0.01
Confidence Interval
(1.18-74.94)
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website